What Researchers Did
The researchers conducted a systematic review to assess the effectiveness and cost-effectiveness of hyperbaric oxygen therapy (HBOT) for non-healing diabetic ulcers, applying their findings to healthcare practices in Ontario, Canada.
What They Found
The abstract highlights that diabetes mellitus affects approximately 2 million Canadians, with 10-15% of these individuals developing foot wounds, equating to 70,000-105,000 people in Ontario. While HBOT is an insured service in Ontario, public coverage for technical costs is limited outside hospitals, and access is constrained by hospital capacity. The abstract does not detail specific effectiveness or cost-effectiveness outcomes from the systematic review.
What This Means for Canadian Patients
Canadian patients with diabetes and non-healing ulcers may face challenges accessing HBOT despite it being an insured service in Ontario. The limited public coverage for technical costs outside hospitals and restricted hospital capacity mean that many patients might not receive this treatment. Improved access could potentially benefit the significant number of Canadians affected by diabetic foot wounds.
Canadian Relevance
This study is highly relevant to Canada as it is an Ontario health technology assessment, directly examining HBOT practices and policies within Ontario, Canada. It addresses diabetic foot ulcers, a Health Canada-recognized complication of diabetes.
Study Limitations
A significant limitation is that the provided abstract describes the problem and context but does not present the specific effectiveness or cost-effectiveness outcomes of the systematic review.